Scientific paper - Original scientific paper
Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis
Multiple Sclerosis Journal, 25 (2019), 9; 1273-1288. https://doi.org/10.1177/1352458519841829

Phelps, Richard; Winston, Jonathan A; Wynn, Daniel; Habek, Mario; Hartung, Hans-Peter; Havrdová, Eva Kubala; Markowitz, Glen S; Margolin, David H; Rodriguez, Claudio E; Baker, Darren P; Coles, Alasdair J

Cite this document

Phelps, R., Winston, J. A., Wynn, D., Habek, M., Hartung, H. P., Havrdová, E. K. ... Coles, A. J. (2019). Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis. Multiple Sclerosis Journal, 25. (9), 1273-1288. doi: 10.1177/1352458519841829

Phelps, Richard, et al. "Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis." Multiple Sclerosis Journal, vol. 25, no. 9, 2019, pp. 1273-1288. https://doi.org/10.1177/1352458519841829

Phelps, Richard, Jonathan A Winston, Daniel Wynn, Mario Habek, Hans Peter Hartung, Eva Kubala Havrdová, Glen S Markowitz, et al. "Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis." Multiple Sclerosis Journal 25, no. 9 (2019): 1273-1288. https://doi.org/10.1177/1352458519841829

Phelps, R., et al. (2019) 'Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis', Multiple Sclerosis Journal, 25(9), pp. 1273-1288. doi: 10.1177/1352458519841829

Phelps R, Winston JA, Wynn D, Habek M, Hartung HP, Havrdová EK, and sur.. Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis. Multiple Sclerosis Journal [Internet]. 2019 August [cited 2024 July 12];25(9):1273-1288. doi: 10.1177/1352458519841829

R. Phelps, et al., "Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis", Multiple Sclerosis Journal, vol. 25, no. 9, pp. 1273-1288, August 2019. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:942822. [Accessed: 12 July 2024]

Please login to the repository to save this object to your list.